By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
Currency | US Dollars |
Share Price | $ 146.17 |
Change Today | $ -2.67 |
% Change | -1.79 % |
52 Week High | $201.44 |
52 Week Low | $118.84 |
Volume | 904,597 |
Shares Issued | 145.80m |
Market Cap | $21,312m |
Beta | 0.00 |
RiskGrade | 259 |
Strong Buy | 7 |
Buy | 6 |
Neutral | 20 |
Sell | 1 |
Strong Sell | 0 |
Total | 34 |
Time | Volume / Share Price |
13:31 | 100 @ $146.17 |
13:31 | 100 @ $146.16 |
13:31 | 100 @ $146.16 |
13:31 | 100 @ $146.14 |
13:31 | 100 @ $146.11 |
You are here: research